Aims/hypothesis Subtyping GAD autoantibody (GADA) responses using affinity measurement allows the identification of GADA-positive children with a family history of type 1 diabetes who are at risk of developing diabetes. Here, we asked whether GADA affinity is a useful marker to stratify the risk of type 1 diabetes in GADA-positive schoolchildren from the general population. Methods GADA affinity was measured by competitive binding experiments with [ 125
Introduction
Type 1 diabetes is one of the most common autoimmune diseases in children and adolescents and is caused by a selective destruction of the insulin-producing beta cells of the pancreatic islets of Langerhans [1, 2] . A characteristic feature of this disease is the occurrence of autoantibodies against beta cell antigens such as autoantibodies to GAD (GADA), insulin (IAA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter-8 (ZnT8A) [3, 4] . The presence of such autoantibodies in the peripheral blood is the first detectable marker of ongoing beta cell destruction. They may appear early in life and predict the development of type 1 diabetes [5] [6] [7] [8] . The risk of diabetes increases with the number of autoantibody markers [9, 10] . In contrast, children who do not develop autoantibodies against multiple beta cell antigens rarely progress to clinical type 1 diabetes during childhood. GADA often appear in older age groups and are preferentially associated with HLA-DRB1*03 haplotypes [11] . The GADA level alone does not predict progression to diabetes, and controversial reports exist with respect to the relevance of GADA epitope reactivity to diabetes progression [12] [13] [14] [15] [16] [17] .
We previously demonstrated that children with a familial predisposition who developed type 1 diabetes had highaffinity GADA before the onset of their disease, whereas those with low-affinity GADA showed no progression of islet autoimmunity [14] . Nevertheless, approximately 90% of children diagnosed with type 1 diabetes have no first-degree relatives with the disease [18] [19] [20] . The intent of the present study was therefore to extend our previous findings in relatives to schoolchildren from the general population. In particular, we asked whether a relationship exists between GADA affinity and other characteristics of GADA such as level and epitope specificity, as well as HLA genotype and the status of autoantibodies to other beta cell antigens.
Methods
Study cohort and samples Samples were obtained from the Karlsburg Type 1 Diabetes Risk Study, in which a total of 11,840 children of a general school population in the northeastern part of Germany were screened for GADA, IAA, IA-2A and islet cell antibodies [21] . Autoantibody-positive children were invited for re-examination to confirm the autoantibody measurements and for HLA genotyping [22] . The study was authorised by the state government of MecklenburgVorpommern (No. VII 233 A-3201-01) and approved by the ethics committee of the University of Greifswald. All participants gave written informed consent to participate in the study. Investigations were carried out in accordance with the principles of the Declaration of Helsinki, as revised in 2008.
For the present study, the sample volume of 97 GADApositive schoolchildren at re-examination was large enough to perform measurements of GADA affinity and epitopes. This sample was defined as the initial sample in our study. The children had a median age of 11.2 years (interquartile range [IQR] 9.6-13.5 years), 44 were male, and none had a firstdegree relative with type 1 diabetes. In addition, a follow-up sample was available for analysis from 95 children (median time since the initial sample 4.9 years, IQR 3.3-6.6 years), and a second follow-up sample from 13 children (median time since the first follow-up sample 3.7 years, IQR 2.1-4.4 years). The children were contacted on follow-up to obtain information on diabetes status (median time from the initial sample to last contact 8.6 years, IQR 5.2-10.9 years).
Islet autoantibody measurements Levels of GADA, IA-2A and IAA were measured by radiobinding assays using [ 125 I]-labelled recombinant human 65 kDa isoform of GAD (GAD65), IA-2 and insulin as previously described [20, 21] . A cut-off level at or above the 98th percentile was used for all autoantibodies [21] . In the 4th Diabetes Antibody Standardization Program 2005 workshop, the GADA and IA-2A assays achieved a diagnostic sensitivity and specificity of 82% and 96% (GADA) and 66% and 100% (IA-2A), respectively [23] , and the IAA assay achieved 58% sensitivity and 97% specificity [24] .
GADA epitope measurements GADA epitope specificity was determined using radiobinding assays on [ 35 S]-methioninelabelled GAD65/67 kDa isoform of GAD (GAD67) chimeric proteins as previously described [17] . Thresholds for positivity were defined as the upper limit in the sera of 50 control participants. The chimeric proteins used were GAD65 1-95 / GAD67 101-593 (GAD N-terminal; GAD65 amino acid 1-95), GAD67 1-243 /GAD65 235-444 /GAD67 453-593 (GAD-MID, the middle section of GAD; GAD65 amino acid 235-444) and GAD67 1-452 /GAD65 445-585 (GAD C-terminal; GAD65 amino acid 445-585). GADA were classified as A (reactive to middle and/or C-terminal GAD65 epitopes), B (reactive to N-terminal GAD65 epitopes only) or C (reactive to none of the GAD65 epitopes represented in the chimeric proteins).
GADA affinity measurements GADA affinity was measured by competitive binding experiments as previously described [14] . Briefly, serum (2 μl) was incubated in duplicate for 48 h at 4ºC in TBST buffer (50 mol/l Tris, 150 mmol/l NaCl, 1% Tween 20, pH 7.4) ]-GAD65 activity added to the test were diluted. For such samples, GADA affinity was calculated from the competitive binding curve obtained with the diluted sample. The reproducibility of GADA affinity measurements was determined from replicates of a GADA-positive serum that was included in each experiment. The CV of GADA affinity measurements was 3% [14] . The calculation of K d values was limited to samples with IC 50 values greater than the concentration of labelled GAD65 (0.05 nmol/l). For samples with an IC 50 <0.05 nmol/l, the mean GADA affinity of the sample was set at >4.0×10 11 l/mol.
HLA typing HLA-DRB1 genotyping was performed using PCR-amplified genomic DNA and nonradioactive oligonucleotide probes as described elsewhere [22] .
Statistical analysis The Mann-Whitney U test was used to compare GADA affinities between groups (epitope specificity, autoantibody status and HLA genotype). Spearman's correlation was used to determine the correlation between variables. The Wilcoxon logrank test was used to compare GADA affinity over time. For all analysis, a two-tailed p value of 0.05 was considered significant. All statistical analyses were performed using GraphPad Prism software (Version 3.01; GraphPad Software).
Results
Schoolchildren from the general population exhibit large variations in GADA affinity The affinity of GADA varied between the 97 GADA-positive schoolchildren and ranged from 5.6×10 6 to >4.0×10 11 l/mol. Competitive GADA binding curves to [ 125 I]-GAD65 were consistent with a one-site binding model in the samples from all the children, suggesting that GADA were of relatively homogeneous affinities within each sample (Fig. 1) . The affinity of GADA correlated with the GADA level (r=0.57; p<0.0001) but was not associated with age (p=0.2). Children carrying the HLA-DRB1*03 allele showed higher GADA affinities (n=28; median >4.0×10 8 to >4.0×10 11 l/mol; p=0.02) (Fig. 2a) . GADA affinity was particularly higher in children with coexisting IAA and/or IA-2A (n=35; median >4.0×10 11 l/mol, IQR 3.9×10 11 to >4.0×10 11 l/mol) compared with those with GADA alone (n = 62; median 3.1 × 10 9 l/mol, IQR 6.2×10 8 to 1.8×10 11 l/mol; p<0.0001) (Fig. 2b) .
High-affinity GADA display a characteristic epitope specificity The GADA response was predominantly directed against the C-terminal (residues 445-585) and/or middle part (residues 235-444) of the GAD65 protein. This epitope reactivity was associated with high GADA affinities (n=70; median >4.0×10 11 l/mol, IQR 4.4×10 9 to >4.0×10 11 l/mol) compared with GADA responses restricted to the N-terminal part (residues 1-95) of the protein, which were associated with lower affinities (n=12; median 9.0×10 8 l/mol, IQR 2.1×10 8 to 2.9×10 9 l/mol; p<0.0001) (Fig. 2c) . Furthermore, GADA levels correlated well with GADA reactivity to the C-terminal (r=0.73; p<0.0001) and middle (r=0.77; p<0.0001) part of GAD65 (Fig. 3a, b ), but not with GADA reactivity to the N-terminal region (r=0.07; p=0.5) (Fig. 3c) . GADA of unknown epitope specificity (i.e. GADA that did not bind to the GAD-MID, C-terminal, or N-terminal constructs) showed variable affinities (median 1.5×10 10 l/mol, IQR 7.7×10 8 to >4.0×10 11 l/mol) (Fig. 2c) .
GADA affinity on follow-up and progression to type 1 diabetes We obtained a first follow-up serum sample from 95 of the 97 GADA-positive schoolchildren, and a second follow-up sample from 13 children. No follow-up sample was available from two multiple islet autoantibody-positive children (GADA affinity 3.1×10 10 and >4.0×10 11 l/mol, respectively). A total of 26 children developed type 1 diabetes (median time from initial sample to diagnosis 6.5 years, IQR 2.8-10.6 years).
GADA affinity remained relatively constant on follow-up in the majority of children (Fig. 4) . Children with multiple islet autoantibodies (n=33) predominantly had GADA affinities of ≥10 10 l/mol. Of these, 29 children remained multiple autoantibody-positive on follow-up, and 21 of them developed diabetes. Four children reverted to single GADA, but two of them nevertheless developed diabetes (Fig. 4c, d) 11 l/mol (sample 2). Both curves are consistent with a one-site binding model contrast, children with single GADA (n=62) showed a broad spectrum of GADA affinities ranging from 10 6 to 10 11 l/mol. Among these, 57 children remained single GADA-positive on follow-up, and two developed diabetes. Five children became multiple islet autoantibody-positive on follow-up (GADA affinity, range 1.2×10 10 to >4.0×10 11 l/mol), and one developed diabetes (Fig. 4a, b) .
GADA affinity, level and epitope specificity define distinct GADA profiles On considering the affinity, level and epitope reactivity of GADA, as well as islet autoantibody status and HLA genotype, several distinct GADA profiles could be identified to stratify the risk of type 1 diabetes in schoolchildren (Fig. 5) .
The first, most frequent GADA profile (profile P1; Fig. 5a, d ) was found in 50 (51.5%) of the 97 GADApositive children. This profile displayed high-affinity GADA with median to high antibody levels and reactivity against the middle and/or C-terminal epitopes of the GAD65 protein. Of the children with this profile, 20 (40%) carried the HLA-DRB1*03 allele, 31 (62%) were multiple islet autoantibodypositive, and 23 (46%) developed type 1 diabetes.
A second GADA profile (profile P2; Fig. 5a ) was also associated with reactivity against the middle and/or C-terminal regions of GAD65, but showed low GADA affinity and low antibody levels. This profile was found in 20 (20.6%) of the 97 children who were all single GADA-positive. Only four of them (20%) carried the HLA-DRB1*03 allele, and one (5%) progressed to type 1 diabetes.
The third GADA profile (profile P3; Fig. 5b , e) was characterised by restricted GADA binding against the N-terminal epitopes of GAD65, low GADA affinity, low antibody levels and low frequency of the HLA-DRB1*03 allele. Twelve (12.4%) children displayed this profile, of whom 11 were single GADA-positive and none progressed to type 1 diabetes.
Finally, 15 (15.5%) children had GADA that did not bind to any of the epitope constructs (profile P4; Fig. 5c, f) . These GADA were of either low or high affinity, had low antibody levels and were found in children with single GADA or multiple islet autoantibodies. Only two children with this fourth GADA profile progressed to type 1 diabetes (both of whom were multiple autoantibody-positive).
A summary of the main characteristics of all the GADA profiles is shown in Fig. 5g . Among multiple islet autoantibody-positive children, profile P1 was the predominant GADA profile (88.6%; Fig. 5j ), whereas single GADApositive children showed a rather variable distribution into the four profiles (Fig. 5h) .
Discussion
Screening for autoantibodies to beta cell antigens is a powerful method to assess the risk of type 1 diabetes [10] . It has recently become evident that besides the autoantibody level, both affinity and epitope specificity may be used to further stratify risk [12, 14, 25, 26] . We were previously able to demonstrate in children who had at least one parent affected by type 1 diabetes that an assessment of GADA affinity and epitope specificity allowed us to define discrete GADA profiles associated with risk of type 1 diabetes [14] . The present study is the first to expand this observation to the general population and to analyse GADA profiles in schoolchildren without a first-degree family history of type 1 diabetes. As in the relatives [14] , we found GADA profiles that were characterised by their GADA affinity and epitope specificity. In particular, children with high-affinity GADA that recognised the middle and/or C-terminal part of GAD65 (profile P1) were at risk of progression to clinical diabetes. IAA and/or IA-2A as well as the HLA-DRB1*03 allele were frequently present in GADApositive children with this profile.
The affinity of GADA varied among the schoolchildren over almost five orders of magnitude and was correlated with GADA levels. Interestingly, GADA binding to the middle and/or C-terminal part of GAD65 could be of high or low affinity, and this was strongly related to the islet autoantibody status. The occurrence of GADA plus IAA and/or IA-2A was predominantly seen in children with high-affinity autoantibodies, confirming previous reports from us and others [25, 27, 28] . In contrast, GADA binding only to the N-terminal part of GAD65 involved predominantly single low-affinity GADA level (KU/l) GADA C-terminal level (AU) Fig. 3 Relationship between GADA levels and epitope binding. The GADA levels of 97 schoolchildren are correlated with the levels of GADA binding to epitopes within (a) GAD65 residues 445-585 (GADA C-terminal) (r=0.73, p<0.0001), (b) GAD65 residues 235-444 (GADA-MID) (r=0.77, p <0.0001), or (c) GAD65 residues 1-95 (GADA N-terminal) (r=0.07, p=0.5). Thresholds for antibody positivity are indicated by broken lines for each epitope specificity. AU, arbitrary units; KU, Karlsburg units antibodies and was not related to the development of diabetes. Overall, low-affinity GADA were rarely found in multiple autoantibody-positive children. GADA profiles were relatively homogenous in schoolchildren with multiple islet autoantibodies and those who developed diabetes, but were highly variable in children who had only GADA. Moreover, children with single lowaffinity GADA could be classified into two profiles according to their binding to epitopes within the middle/C-terminal region of GAD65 (profile P2) or within the N-terminal region only (profile P3). Besides the absence of reactivity to multiple islet autoantigens, both profiles were further characterised by relatively low GADA levels and a low frequency of the HLA-DRB1*03 allele. Only one child displaying profile P2, and no child with profile P3, developed type 1 diabetes during the observation time. These findings in the GADA-positive children from the general population are consistent with what we and others have previously observed for GADA, IAA or IA-2A in first-degree relatives and in IAA-positive children without a familial predisposition [14, 25, 26, 28, 29] .
A limitation of our study is that, in contrast to the BABYDIAB study [8] , only sera from schoolchildren with established GADA responses have been included, and the age at autoantibody seroconversion in these children was not known. This may explain the low number of changes from single GADA to multiple autoantibody-positive status. Only a few single GADA-positive children developed IAA and/or IA-2A on follow-up. Another limitation of our study is that the schoolchildren were not tested for the presence of ZnT8A. Therefore, we cannot exclude the possibility that some of the schoolchildren who were classified as single GADA-positive may have had ZnT8A and would shift to the multiple islet autoantibody-positive group. ZnT8A have been associated with rapid disease progression in the relatives of patients with [30] [31] [32] , which we did not observe for schoolchildren with GADA only in the present study. Yet the selected cohort of schoolchildren in our study allowed for an analysis of the development of GADA affinity and epitope specificity over time. Since the children are still being followed prospectively into adulthood, we cannot identify the timeframe within which children with a specific GADA profile will progress to clinical diabetes. Nevertheless, our findings confirm immune profiles found in the relatives of type 1 diabetes patients [14] . Therefore, the data support the hypothesis that findings related to the immune pathogenesis of type 1 diabetes identified in people with a familial predisposition can be transferred to the general population. Recent advances in the reliability and specificity of islet autoantibody measurements, such as electrochemiluminescence-based antibody assays [33] , may further improve screening in the general population. In summary, we conclude that an assessment of GADA affinity and epitope specificity in addition to the GADA level, islet autoantibody status and HLA genotype allows for the determination of several distinct GADA profiles and a more accurate stratification of the risk of type 1 diabetes in the general population. Furthermore, GADA affinity could be a useful diagnostic marker for the recruitment of people from the general population to studies on the prevention of type 1 diabetes.
